 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (June 2022) |
| Company type | Public company |
|---|---|
| ISIN | CH0363463438 |
| Industry | |
| Founded | 2017 |
| Founder | Jean-Paul Clozel, Martine Clozel |
| Headquarters | Allschwil, Switzerland |
Key people | Jean-Paul Clozel (CEO), Martine Clozel (Chief Scientific Officer), Guy Braunstein (Chief Medical Officer) |
| Products | clazosentan, daridorexant |
| Revenue | - 828 million CHF (2023) |
Number of employees | > 1200 (2022) |
| Website | http://www.idorsia.ch; http://www.idorsia.com |
Idorsia is a Swiss pharmaceutical research company in Allschwil, near Basel, Switzerland.